These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 880821)

  • 1. Long-term contraception by steroid releasing implants. VI. Serum concentrations of norethindrone in women bearing a single silastic implant releasing norethindrone acetate.
    Hillier SG; Jha P; Griffiths K; Laumas KR
    Contraception; 1977 Apr; 15(4):473-88. PubMed ID: 880821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of norethindrone acetate released from a single silastic implant on serum FSH, LH, progesterone and estradiol-17beta of women during first eight months of treatment.
    Rahman SA; Jha P; Laumas V; Jain AK; Dileepkumar ; Takkar D; Hingorani V; Laumas KR
    Contraception; 1977 Nov; 16(5):487-97. PubMed ID: 590011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term contraception by a single silastic implant-D containing norethindrone acetate in women: a clinical evaluation.
    Takkar D; Anandalaxmi PN; Chandra VL; Bhatnagar S; Yadav HS; Laumas KR; Hingorani V; Krishna U; Mandleker A; Purandare VN; Goel V; Adatia A; Virker KD
    Contraception; 1978 Apr; 17(4):341-54. PubMed ID: 648156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subdermal norethindrone pellets -- a method for contraception?
    Odlind V; Moo-Young AJ; Gupta GN; Weiner E; Johansson ED
    Contraception; 1979 Jun; 19(6):639-48. PubMed ID: 487813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term contraception by steroid-releasing implants. II. A preliminary report on long-term contraception by a single silastic implant containing norethindrone acetate (ENTA) in women.
    Bhatnagar S; Srivastava UK; Takkar D; Chandra VL; Hingorani V; Laumas KR
    Contraception; 1975 May; 11(5):505-21. PubMed ID: 1139938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of climacteric and postmenopausal women with 17-beta-oestradiol and norethisterone acetate.
    Furuhjelm M; Carlström K
    Acta Obstet Gynecol Scand; 1977; 56(4):351-61. PubMed ID: 602703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of fertility with oral medication.
    Diddle AW; Watts GF; Gardner WH; Williamson PJ
    West J Surg Obstet Gynecol; 1964; 72():222-9. PubMed ID: 12305556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of norethindrone acetate in women after the insertion of a single subdermal implant releasing norethindrone acetate.
    Singh H; Uniyal JP; Jha P; Takker D; Murguesan K; Hingorani V; Laumas KR
    Acta Endocrinol (Copenh); 1982 Feb; 99(2):302-8. PubMed ID: 7058686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration.
    Hiroi M; Stanczyk FZ; Goebelsmann U; Brenner PF; Lumkin ME; Mishell DR
    Steroids; 1975 Sep; 26(3):373-86. PubMed ID: 1198624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of norethisterone in women with subcutaneous implants of norethisterone acetate.
    Joshi JV; Naik VK; Joshi UM
    Indian J Med Res; 1979 Oct; 70():625-31. PubMed ID: 541006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating levels of norethindrone in women with a single silastic implant.
    Goyal V; Joshi UM; Naik VK
    Contraception; 1978 Apr; 17(4):375-82. PubMed ID: 648158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily serum follicle-stimulating hormone, luteinizing hormone, and plasma testosterone and androstenedione in hirsute women with polycystic sclerotic ovaries: effects of diethylstilbestrol and norethindrone acetats.
    Daane TA; Dignam WJ; Frankland MV; Simmer HH; Parlow AF
    Am J Obstet Gynecol; 1973 Oct; 117(3):392-9. PubMed ID: 4729733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
    Goldzieher JW; Chenault CB; de la Peña A; Dozier TS; Kraemer DC
    Fertil Steril; 1978 Nov; 30(5):522-33. PubMed ID: 214353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serium protein-bound carbohydrate and seromucoid levels during long-acting progestational contraceptive therapy.
    Saleh FM
    Contraception; 1977 Oct; 16(4):399-407. PubMed ID: 923250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A radioimmunoassay for norethindrone (NET): measurement of serum NET concentrations following ingestion of NET-containing oral contraceptive steroids.
    Stanczyk FZ; Brenner PF; Mishell DR; Ortiz A; Gentzschein EK; Goebelsmann U
    Contraception; 1978 Dec; 18(6):615-33. PubMed ID: 750188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver function tests in patients on oral progestogens.
    Engineer AD; Gupta V; Tandon P
    J Obstet Gynaecol India; 1968 Apr; 18(2):598-605. PubMed ID: 12331828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oestriol deficiency, a possible factor in the aetiology of thrombo-embolism in pill users.
    Zaki K; Sami G; Nour H
    Egypt Popul Fam Plann Rev; 1972 Jun; 5(1):19-24. PubMed ID: 12256026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of low dose oral contraceptives containing norethindrome and ethinyl estradiol on serum levels of progesterone and pituitary gonadotropins.
    McGuire JL; Bariso CD; Yuliano E; Hume RJ; Pasquale SA
    Contraception; 1975 Mar; 11(3):329-38. PubMed ID: 1116369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum lipids and lipoproteins during treatment with oral contraceptives containing natural and synthetic oestrogens. A controlled double-blind investigation.
    Bostofte E; Hemmingsen L; Møller KJ; Serup J; Weber T
    Acta Endocrinol (Copenh); 1978 Apr; 87(4):855-64. PubMed ID: 347855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of the oral contraceptive estrogen burden by alternate day estrogen administration.
    Segre EJ; Henzl MR; Giner J; Scheel C; Bessler S
    Contraception; 1975 Aug; 12(2):155-74. PubMed ID: 1139955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.